#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
Click to read this study in The Lancet Oncology.
Source: 2minutemedicine.com
Stay updated with breaking news from Hematologic Malignancy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Click to read this study in The Lancet Oncology.
Researchers performed a systematic review and meta-analysis following the PRISMA guidelines.
Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors
Studies indicate the level of risk may not warrant such a broad, catastrophizing narrative
New research looks at best candidates for this treatment